BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 34745101)

  • 41. Protocol for qRT-PCR analysis from formalin fixed paraffin embedded tissue sections from diffuse large b-cell lymphoma: Validation of the six-gene predictor score.
    Tekin N; Omidvar N; Morris TP; Conget P; Bruna F; Timar B; Gagyi E; Basak R; Naik O; Auewarakul C; Sritana N; Levy D; Cerci JJ; Bydlowski SP; Pereira J; Dimamay MP; Natividad F; Chung JK; Belder N; Kuzu I; Paez D; Dondi M; Carr R; Ozdag H; Padua RA
    Oncotarget; 2016 Dec; 7(50):83319-83329. PubMed ID: 27825111
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comprehensive analysis of a 14 immune-related gene pair signature to predict the prognosis and immune features of gastric cancer.
    Liu C; Chen B; Huang Z; Hu C; Jiang L; Zhao C
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107074. PubMed ID: 33049494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
    Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
    BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy.
    Chu MP; Lieffers J; Ghosh S; Belch A; Chua NS; Fontaine A; Sangha R; Turner RA; Baracos VE; Sawyer MB
    J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):298-304. PubMed ID: 27897411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene expression-based risk score in diffuse large B-cell lymphoma.
    Bret C; Klein B; Moreaux J
    Oncotarget; 2012 Dec; 3(12):1700-10. PubMed ID: 23482333
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
    Zhao C; Huang R; Zeng Z; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Yan P; Huang Z; Shi J
    Aging (Albany NY); 2021 May; 13(10):14131-14158. PubMed ID: 34001679
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression.
    Sun R; Zheng Z; Wang L; Cheng S; Shi Q; Qu B; Fu D; Leboeuf C; Zhao Y; Ye J; Janin A; Zhao WL
    Mol Oncol; 2021 Jan; 15(1):246-261. PubMed ID: 33107145
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
    Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
    J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 50. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
    Ruppert AS; Dixon JG; Salles G; Wall A; Cunningham D; Poeschel V; Haioun C; Tilly H; Ghesquieres H; Ziepert M; Flament J; Flowers C; Shi Q; Schmitz N
    Blood; 2020 Jun; 135(23):2041-2048. PubMed ID: 32232482
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients.
    Li LQ; Zhang LH; Zhang Y; Lu XC; Zhang Y; Liu YK; Khader MA; Jia-Wen ; Tao-Liu ; Li JZ
    Aging (Albany NY); 2020 Nov; 12(22):22906-22926. PubMed ID: 33203792
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients.
    Coutinho R; Lobato J; Esteves S; Cabeçadas J; Gomes da Silva M
    Ann Hematol; 2019 Aug; 98(8):1937-1946. PubMed ID: 30949752
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical, inflammatory and immunohistochemical features in a cohort of Peruvian patients with diffuse large B-cell lymphoma.
    Castro D; Beltrán B; Quiñones MDP; Pachas C; Huerta Y; Lalupu K; Mendoza R; Castillo JJ
    Leuk Res; 2021 Mar; 102():106513. PubMed ID: 33561632
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma.
    Merdan S; Subramanian K; Ayer T; Van Weyenbergh J; Chang A; Koff JL; Flowers C
    Blood Cancer J; 2021 Jan; 11(1):2. PubMed ID: 33414466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management.
    Beltran BE; Castro D; Paredes S; Miranda RN; Castillo JJ
    Am J Hematol; 2020 Apr; 95(4):435-445. PubMed ID: 32072672
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel anoikis-related signature predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma.
    Guan M; Zhao H; Zhang Q; Li L; Wang X; Tang B
    Expert Rev Mol Diagn; 2024 May; 24(5):439-457. PubMed ID: 38709202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognosis of localized diffuse large B-cell lymphoma in younger patients.
    Møller MB; Christensen BE; Pedersen NT
    Cancer; 2003 Aug; 98(3):516-21. PubMed ID: 12879468
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.
    Barrans SL; Carter I; Owen RG; Davies FE; Patmore RD; Haynes AP; Morgan GJ; Jack AS
    Blood; 2002 Feb; 99(4):1136-43. PubMed ID: 11830458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.